Screener
Lexicon Pharmaceuticals LXRX Business Segments — Other Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherExpenses.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 6,964 | 6,466 | 13,408 | 14,292 |
| Other segment expense (1) | 3,336 | 3,271 | 6,414 | 6,072 |
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 |
| (Loss) income from operations | (26,540) | 3,736 | (27,536) | (21,943) |
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 |
| Loss on early extinguishment of debt | (4,349) | — | (4,349) | — |
| Net (loss) income | $(31,775) | $3,252 | $(32,818) | $(22,043) |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — other expenses?
- Lexicon Pharmaceuticals (LXRX) reported business segments — other expenses of $2.61M in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — other expenses changed year-over-year?
- Lexicon Pharmaceuticals's business segments — other expenses increased by 12.6% year-over-year, from $2.32M to $2.61M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — other expenses?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — other expenses has grown at a 44.2% compound annual growth rate (CAGR), from $2.78M to $8.34M.
- What does business segments — other expenses mean?
- Non-operating costs or peripheral financial charges that impact the segment's net financial position, such as interest expense or foreign exchange losses. These items are distinct from core operational costs and provide insight into the segment's financial leverage and external risk exposure. Monitoring these helps isolate the impact of non-core activities on the segment's bottom line.
Ask your AI about Lexicon Pharmaceuticals's business segments — other expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude